Basic Search
|
Geographic Searches
|
Advanced Search |
MegadealsSubsidy Tracker: Industry Summary Page
Major Industry: pharmaceuticals
Subsidy Total: $3,972,211,621
Number of Awards: 2,783
Time Period: Earliest year of data: 1975. Availability of data for earlier years varies greatly from program to program. The majority of the listings for this industry are for the period since 2012.
Notes: The dollar total above adjusts for the fact that there is an overlap between the amounts in one or more Megadeal entries and those of one or more of the other entries. The total includes only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. Dollar totals do not include awards for which no subsidy value is disclosed.
Top 10 Parent Companies | Total Subsidy $ | Number of Awards |
Eli Lilly | $601,741,368 | 77 |
Regeneron Pharmaceuticals | $469,433,071 | 112 |
AstraZeneca | $436,175,713 | 52 |
Pfizer | $332,313,011 | 206 |
Novo Holdings A/S | $241,475,902 | 102 |
Elanco Animal Health | $189,545,200 | 7 |
Merck | $153,889,367 | 82 |
AbbVie | $145,729,008 | 68 |
Johnson & Johnson | $111,279,431 | 124 |
Bristol-Myers Squibb | $110,616,473 | 81 |
Individual Subsidy Records:
Warning: Attempt to read property "post_title" on string in
/usr/home/goodjobsfirst/public_html/subsidytrackerlive/function.php on line
2057
Warning: Attempt to read property "post_name" on string in
/usr/home/goodjobsfirst/public_html/subsidytrackerlive/function.php on line
2059
Company | Parent | Location | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value | Type of Subsidy |
Exelixis, Inc. | Exelixis | California | state | 2020 | $7,000,000 | | tax credit/rebate |
Genentech USA, Inc | Roche | Oregon | state | 2019 | $500,260 | | grant |
Genentech USA, Inc | Roche | Oregon | state | 2020 | $1,573,000 | | grant |
Abbott Vascular Inc | Abbott Laboratories | California | state | 2021 | $603,200 | | training reimbursement |
Boehringer Ingelheim Fremont Inc | Boehringer Ingelheim | California | state | 2021 | $898,743 | | training reimbursement |
Genentech USA Inc | Roche | California | state | 2021 | $68,185 | | training reimbursement |
Abbott Vascular Inc | Abbott Laboratories | California | state | 2022 | $198,000 | | training reimbursement |
Baxalta Us Inc | Takeda Pharmaceutical | California | state | 2022 | $20,998 | | training reimbursement |
Novo Nordisk US Bio Production Inc | Novo Holdings A/S | New Hampshire | state | 2022 | undisclosed | | tax credit/rebate |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $6,000,000 | | tax credit/rebate |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $3,450,000 | | tax credit/rebate |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $3,255,000 | | tax credit/rebate |
Pfizer | Pfizer | Tennessee | state | 2021 | undisclosed | | property tax abatement |
Pfizer | Pfizer | Tennessee | state | 2021 | undisclosed | | property tax abatement |
Pfizer | Pfizer | Tennessee | state | 2021 | undisclosed | | property tax abatement |
Pfizer | Pfizer | Tennessee | state | 2022 | undisclosed | | property tax abatement |
Pfizer | Pfizer | Tennessee | state | 2022 | undisclosed | | property tax abatement |
Pfizer | Pfizer | Tennessee | state | 2022 | undisclosed | | property tax abatement |
Merck & Co., Inc. | Merck | Virginia | state | 2019 | $7,500,000 | | grant |
Bausch & Lomb | Bausch Health | Virginia | state | 2023 | $300,000 | | grant |
Abbott Laboratories | Abbott Laboratories | Virginia | state | 2020 | $300,000 | | grant |
Merck | Merck | Virginia | state | 2019 | $1,300,000 | | grant |
Merck | Merck | Virginia | state | 2015 | $1,500,000 | | grant |
Merck | Merck | Virginia | state | 2007 | $500,000 | | grant |
PBM Nutritionals | Perrigo | Vermont | state | 2012 | $144,711 | | training reimbursement |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2022 | $2,645,382 | | tax credit/rebate |
Abiomed Inc. | Johnson & Johnson | Massachusetts | state | 2021 | $675,000 | | tax credit/rebate |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Massachusetts | state | 2021 | $1,950,000 | | tax credit/rebate |
EMD Holding Corporation | Merck KGaA (EMD) | Massachusetts | state | 2021 | $1,725,000 | | tax credit/rebate |
Pfizer Inc. | Pfizer | West Virginia | state | 2010 | undisclosed | | tax credit/rebate |
Pfizer Inc | Pfizer | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Pfizer Inc | Pfizer | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2015 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2016 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2017 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2016 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2018 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Novartis Corporation | Novartis | West Virginia | state | 2015 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2010 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2015 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2016 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2015 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2016 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc. | Viatris | West Virginia | state | 2011 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2012 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2013 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2014 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2015 | undisclosed | | tax credit/rebate |
Mylan Inc | Viatris | West Virginia | state | 2016 | undisclosed | | tax credit/rebate |
Eli Lilly & Company | Eli Lilly | Indiana | state | 2022 | $293,100,000 | | MEGADEAL |
Bristol Myers Squibb Company | Bristol-Myers Squibb | Arizona | state | 2022 | $3,000,000 | | tax credit/rebate |
Alere, Inc | Abbott Laboratories | Missouri | state | 2017 | $3,220,080 | | tax credit/rebate |
Novozymes Blair, Inc. | Novo Holdings A/S | Nebraska | state | 2023 | $475,775 | | tax rebate |
Bausch & Lomb | Bausch Health | Virginia | state | 2020 | $210,000 | | grant |